A detailed history of Loomis Sayles & CO L P transactions in United Therapeutics Corp stock. As of the latest transaction made, Loomis Sayles & CO L P holds 148,481 shares of UTHR stock, worth $54.2 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
148,481
Previous 231,889 35.97%
Holding current value
$54.2 Million
Previous $73.9 Million 27.97%
% of portfolio
0.07%
Previous 0.1%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$311.04 - $363.55 $25.9 Million - $30.3 Million
-83,408 Reduced 35.97%
148,481 $53.2 Million
Q2 2024

Aug 13, 2024

SELL
$228.26 - $319.04 $4.6 Million - $6.42 Million
-20,135 Reduced 7.99%
231,889 $73.9 Million
Q1 2024

May 14, 2024

SELL
$210.76 - $249.51 $425,735 - $504,010
-2,020 Reduced 0.8%
252,024 $57.9 Million
Q4 2023

Feb 13, 2024

SELL
$214.88 - $256.94 $2.42 Million - $2.89 Million
-11,255 Reduced 4.24%
254,044 $55.9 Million
Q3 2023

Nov 09, 2023

SELL
$211.82 - $248.24 $1.06 Million - $1.24 Million
-4,984 Reduced 1.84%
265,299 $59.9 Million
Q2 2023

Aug 11, 2023

BUY
$205.19 - $232.99 $2.27 Million - $2.57 Million
11,044 Added 4.26%
270,283 $59.7 Million
Q1 2023

May 11, 2023

BUY
$212.99 - $276.17 $12.1 Million - $15.7 Million
56,781 Added 28.05%
259,239 $58.1 Million
Q4 2022

Feb 10, 2023

SELL
$205.95 - $280.43 $207,391 - $282,393
-1,007 Reduced 0.49%
202,458 $56.3 Million
Q3 2022

Nov 14, 2022

BUY
$203.3 - $244.17 $7.65 Million - $9.19 Million
37,643 Added 22.7%
203,465 $42.6 Million
Q2 2022

Aug 05, 2022

BUY
$174.81 - $241.14 $16.8 Million - $23.2 Million
96,169 Added 138.07%
165,822 $39.1 Million
Q1 2022

May 13, 2022

SELL
$166.16 - $213.96 $676,935 - $871,673
-4,074 Reduced 5.53%
69,653 $12.5 Million
Q4 2021

Feb 14, 2022

BUY
$184.32 - $216.08 $38,707 - $45,376
210 Added 0.29%
73,727 $15.9 Million
Q3 2021

Nov 12, 2021

SELL
$179.86 - $214.88 $400,907 - $478,967
-2,229 Reduced 2.94%
73,517 $13.6 Million
Q2 2021

Aug 13, 2021

SELL
$170.47 - $211.93 $55,743 - $69,301
-327 Reduced 0.43%
75,746 $13.6 Million
Q1 2021

May 17, 2021

SELL
$153.94 - $174.85 $876,534 - $995,595
-5,694 Reduced 6.96%
76,073 $12.7 Million
Q4 2020

Feb 12, 2021

SELL
$101.87 - $151.79 $2.75 Million - $4.09 Million
-26,964 Reduced 24.8%
81,767 $12.4 Million
Q3 2020

Nov 12, 2020

SELL
$99.9 - $121.13 $248,251 - $301,008
-2,485 Reduced 2.23%
108,731 $11 Million
Q2 2020

Aug 14, 2020

SELL
$92.74 - $125.82 $154,319 - $209,364
-1,664 Reduced 1.47%
111,216 $13.5 Million
Q1 2020

May 15, 2020

BUY
$79.39 - $115.35 $1.13 Million - $1.65 Million
14,294 Added 14.5%
112,880 $10.7 Million
Q4 2019

Feb 14, 2020

SELL
$78.31 - $95.34 $60,925 - $74,174
-778 Reduced 0.78%
98,586 $8.68 Million
Q3 2019

Nov 13, 2019

BUY
$74.85 - $85.99 $1.82 Million - $2.09 Million
24,354 Added 32.47%
99,364 $7.92 Million
Q2 2019

Aug 14, 2019

BUY
$76.06 - $120.81 $5.71 Million - $9.06 Million
75,010 New
75,010 $5.86 Million
Q1 2018

May 11, 2018

SELL
$107.21 - $151.94 $9,220 - $13,066
-86 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$118.58 - $151.28 $6,166 - $7,866
-52 Reduced 37.68%
86 $13,000
Q3 2017

Nov 14, 2017

SELL
$114.6 - $136.81 $6,646 - $7,934
-58 Reduced 29.59%
138 $16,000
Q2 2017

Aug 14, 2017

BUY
N/A
196
196 $25,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.6B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Loomis Sayles & CO L P Portfolio

Follow Loomis Sayles & CO L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.